THERAtRAME discovers and develops first-in-class small molecules targeting the tRNA epitranscriptomics for the benefit of cancer patients.
THERAtRAME discovers and develops new small molecule inhibitors targeting the tRNA epitranscriptomics to cure patients with untreatable cancer.
The THERAtRAME discovery platform integrates unique sets of technologies to discover, develop and position new drugs to beat reluctant cancers. tRNA epitranscriptomics represents a new promising area for drug discovery in oncology.
THERAtRAME ambitions to become a leader in the development and positioning of novel cancer therapies, bringing new hope to patients.